Literature DB >> 23317526

Sero-epidemiology of human immunodeficiency virus, hepatitis B and C viruses, and syphilis infections among first-time blood donors in Edéa, Cameroon.

Jean Jacques N Noubiap1, Walburga Yvonne A Joko, Jobert Richie N Nansseu, Ulrich Gaël Tene, Christian Siaka.   

Abstract

BACKGROUND: Blood safety remains an issue of major concern in transfusion medicine in sub-Saharan Africa. Blood-borne agents such as the human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV), and Treponema pallidum are among the greatest threats to blood safety for the recipient. This study aimed to determine the seroprevalence and risk factors of HIV, HCV, HBV, and syphilis infections among first-time blood donors at the new hospital-based blood bank in Edéa, Cameroon.
METHODS: We carried out a retrospective analysis of blood donor data recorded between December 2011 and May 2012 at the blood bank of the Edéa Regional Hospital. Antibodies to HIV types 1 and 2 were screened with the Determine and ImmunoComb tests. Hepatitis B surface antigen and antibodies to HCV were detected using DIASpot test strips. Syphilis was diagnosed using the Venereal Disease Research Laboratory (VDRL) test and the Treponema pallidum hemagglutination assay (TPHA).
RESULTS: A total of 543 blood donors were included, among whom 349 (64.3%) were family replacement donors. One hundred and fifteen donors (21.2%) were infected with at least one pathogen. The overall seroprevalence rates of HIV, HBV, HCV, and syphilis were 4.1%, 10.1%, 4.8%, and 5.7%, respectively. We found a total of 26 dual infections. The most common combinations were HBV-HCV and HBV-HIV. There was a significant association between HIV and HBV infections (adjusted odds ratio (aOR) 3.46, 95% CI 1.29-9.39; p=0.014), and between HBV and HCV infections (aOR 2.81, 95% CI 1.02-10.12; p=0.036). Compared to voluntary donors, family replacement donors were significantly more infected by at least one screened pathogen (aOR 1.81, 95% CI 1.14-2.88; p=0.013), and more infected specifically by HIV (aOR 3.66, 95% CI 1.07-12.55; p=0.039) and syphilis (aOR 2.81, 95% CI 1.05-7.46; p=0.039).
CONCLUSIONS: Our findings indicate that blood safety remains a major problem in Cameroon where hospital-based blood banks and family replacement donors are predominant. There is an urgent need for a national blood transfusion program in Cameroon that will establish a nationally coordinated blood transfusion service based on the principles of voluntary regular non-remunerated blood donation.
Copyright © 2012 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Blood donors; Cameroon; HBV; HCV; HIV; Syphilis

Mesh:

Substances:

Year:  2013        PMID: 23317526     DOI: 10.1016/j.ijid.2012.12.007

Source DB:  PubMed          Journal:  Int J Infect Dis        ISSN: 1201-9712            Impact factor:   3.623


  48 in total

1.  Epidemiology of hepatitis C viral infection in Faisalabad, Pakistan: a retrospective study (2010-2012).

Authors:  Muhammad Arif Maan; Fatma Hussain; Muhammad Jamil
Journal:  Afr Health Sci       Date:  2014-12       Impact factor: 0.927

2.  Hepatitis C in Cameroon: What is the progress from 2001 to 2016?

Authors:  Borris Rosnay Tietcheu Galani; Richard Njouom; Paul Fewou Moundipa
Journal:  J Transl Int Med       Date:  2016-12-30

3.  The Prevalence of Transfusion Transmitted Infections among Blood Donors in Pakistan: A Retrospective Study.

Authors:  Mahwish Majid Bhatti; Ayesha Junaid; Fouzia Sadiq
Journal:  Oman Med J       Date:  2022-05-31

Review 4.  Hepatitis B virus burden in developing countries.

Authors:  Rosa Zampino; Adriana Boemio; Caterina Sagnelli; Loredana Alessio; Luigi Elio Adinolfi; Evangelista Sagnelli; Nicola Coppola
Journal:  World J Gastroenterol       Date:  2015-11-14       Impact factor: 5.742

5.  Prevalence and vaccination coverage of Hepatitis B among healthcare workers in Cameroon: A national seroprevalence survey.

Authors:  Chanceline Bilounga Ndongo; Lucrèce Eteki; Mark Siedner; Rose Mbaye; Jennifer Chen; Rodrigue Ntone; Olivier Donfack; Brian Bongwong; Rachel Essaka Evoue; Florence Zeh; Richard Njouom; Georges Nguefack-Tsague; Georges Alain Etoundi Mballa; Magloire Biwole Sida; Yap Boum
Journal:  J Viral Hepat       Date:  2018-08-28       Impact factor: 3.728

6.  Characterization of Hepatitis C Virus Recombination in Cameroon by Use of Nonspecific Next-Generation Sequencing.

Authors:  James C Iles; Richard Njouom; Yacouba Foupouapouognigni; David Bonsall; Rory Bowden; Amy Trebes; Paolo Piazza; Ellie Barnes; Jacques Pépin; Paul Klenerman; Oliver G Pybus
Journal:  J Clin Microbiol       Date:  2015-07-22       Impact factor: 5.948

7.  The Acute Chest Syndrome in Cameroonian children living with sickle cell disease.

Authors:  Jobert Richie N Nansseu; Anastasie Nicole Alima Yanda; David Chelo; Sandra A Tatah; Hubert D Mbassi Awa; Judith Seungue; Paul Olivier N Koki
Journal:  BMC Pediatr       Date:  2015-09-21       Impact factor: 2.125

8.  Hepatitis B and C Co-Infections in Some HIV-Positive Populations in Cameroon, West Central Africa: Analysis of Samples Collected Over More Than a Decade.

Authors:  Jean Jacques N Noubiap; Peter V Aka; Aubin J Nanfack; Lucy A Agyingi; Johnson N Ngai; Phillipe N Nyambi
Journal:  PLoS One       Date:  2015-09-15       Impact factor: 3.240

9.  Prevalence, infectivity and correlates of hepatitis B virus infection among pregnant women in a rural district of the Far North Region of Cameroon.

Authors:  Jean Jacques N Noubiap; Jobert Richie N Nansseu; Shalom Tchokfe Ndoula; Jean Joel R Bigna; Ahmadou M Jingi; Joël Fokom-Domgue
Journal:  BMC Public Health       Date:  2015-05-02       Impact factor: 3.295

10.  Trends in serological markers of transfusion transmissible infections in blood donations at the Bamenda Hospital-based Blood Service, Cameroon.

Authors:  Moses Samje; Victor N Fondoh; Georges Nguefack-Tsague; Laure K J Kamalieuk; Dora Mbanya; Edward L Murphy; Claude T Tagny
Journal:  Transfus Clin Biol       Date:  2021-06-05       Impact factor: 1.406

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.